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2ABSTRACT
Regulatory T cells (Treg) actively regulate alloimmune responses and
promote transplantation tolerance. Polyclonal anti-thymocyte globulin
(ATG), a widely used induction therapy in clinical organ transplantation,
depletes peripheral T cells. However, resistance to tolerance induction is
seen with certain T cell depleting strategies and is attributed to alterations
in the balance of naïve, memory and regulatory T cells. Here we report a
novel reagent, murine ATG (mATG), depletes T cells but preferentially
spares CD25+ natural Tregs which limit skewing of T cell repertoire toward
T-effector-memory (Tem) phenotype among the recovering T cells. T-cell
depletion with mATG combined with CTLA4Ig and Sirolimus synergize to
prolong graft survival by tipping the Treg/Tem balance further in favor of Tregs
by preserving Tregs, facilitating generation of new Tregs by a conversion
mechanism and limiting Tem expansion in response to alloantigen and
homeostatic proliferation. These results provide the rationale for translating
such novel combination therapies to promote tolerance in primate and
human organ transplantation.
3INTRODUCTION
Allograft tolerance may be viewed as a balance between pro-inflammatory
and anti-inflammatory forces, where different subsets of T cells can interact
to create the appropriate environment for long-term graft acceptance.
Regulatory T cells (Tregs), a T cell subset involved in modulating the
immune response (32), have been demonstrated to play a critical role in
preventing autoimmune diseases (30), regulating immune response during
infectious diseases (29), maintaining feto-meternal tolerance (1), and also
preventing allograft rejection in transplantation (15). Consequently, there is
great interest in harnessing the power of Tregs to therapeutic advantage
and indeed ex-vivo expanded natural CD4+CD25+ Treg therapy has been
used to prevent experimental acute allograft rejection (38). On the other
hand T effector cells are thought to play a major part in mediating acute
and chronic allograft rejection (4). It has been proposed that tolerance may
be viewed not as an “all or none” phenomenon but rather as a balance
between these different subsets of T cells which can interact to create the
appropriate environment for a long-term graft acceptance under a variety
immunosuppressive treatment (28).
ATG, a polyclonal T cell depleting agent, has been used clinically since the
early 80’s as induction therapy and for treatment of acute rejection in solid
organ transplantation (2, 33). It consists of purified IgG fraction of sera from
rabbits or horses. Rabbit ATG, produced by immunizing rabbits with fresh
human thymocytes, is probably the most widely used and studied
polyclonal ATG preparation. Both experimental and clinical studies of ATG
report profound T cell depletion through complement-dependent lysis or
4activation associated apoptosis, which is believed to be the key
mechanism of its action by reducing the alloreactive T cell repertoire and
frequency (13, 21, 2, 20, 16). Other potential mechanisms of action include
modulation of surface adhesion receptor molecules or chemokine receptor
expression (7). However the exact mechanisms of its action are still
unknown and an ever-expanding array of target antigens is being identified
in ATG preparations (24). Others and we have reported that besides
profound peripheral T cell depletion, ATG modulates the immune response
through its effects on the function of many other immune cell types,
including, B cells, monocytes/macrophages, dendritic cells (DC) and
regulatory T cells (Tregs) (27, 19, 24). However, resistance to tolerance
induction is seen with certain T cell depleting strategies and is attributed to
alterations in the balance of naive, memory and Treg cells (26). Our group
has previously demonstrated that low dose ATG can expand Tregs ex vivo,
inviting a fresh look at the tolerogenic potential of this T cell depletion
strategy (19). Similarly, sirolimus (SRL), another widely used
immunosuppressive agent in clinical transplantation, is thought to expand
naturally occurring Tregs. Further, strategies to block T cell costimulatory
pathway prolong allograft survival in rodents and primates through
expansion of CD4+CD25+ regulatory T cells in certain situations, and are
currently undergoing clinical development in kidney transplantation (8, 9,
34, 35, 17) providing the rationale to combine ATG with SRL and CTLA4Ig
to promote regulation and long-term allograft survival. We therefore tested
the effect of combined ATG, SRL and costimulatory blockade in vivo in a
fully allogeneic mouse skin allograft model. This is the first report to
establish that mATG preserves CD25+ natural Tregs which limit skewing of
5T cell repertoire toward Teff/mem phenotype among the recovering T cells
and that simultaneous T-cell depletion combined with SRL and
costimulatory blockade synergize to prolong allograft survival by limiting
the effector-memory alloreactive T-cell pool and that this effect is
dependent on CD25+ Tregs in a clinically relevant stringent transplant
model. These data emphasize the advantage of a novel strategy combining
mATG with T cell costimulatory blockade to preserve Tregs and limit
homeostatic proliferation of effector and memory T cells and provide the
rationale to translate such a strategy to promote tolerance in human organ
transplantation.
6RESULTS
Generation and characterization of mATG
Murine ATG was generated by immunizing rabbits with a mixture of
thymocytes from 8 different strains of mice (C57BL/6, BALB/c, DBA/2, 129,
C3H, SJL, Swiss Webster, ICR). Thymocyte suspensions were prepared
from extracted thymuses and New Zealand white rabbits were immunized
twice, 2 weeks apart and terminally bled 2 weeks following second
immunization (Millbrook Immunoserv, Amherst, MA). Total rabbit IgG from
the resulting serum was purified with a process analogous to that used for
Thymoglobulin. Control rabbit IgG was similarly purified from whole normal
rabbit serum (Sigma-Aldrich, St Louis, MO).
mATG prolongs allograft survival by depleting naïve T cells and
preserving natural Tregs
We first examined the depletion effect of mATG in naïve mice (day 7 after
depletion with mATG). As expected, mATG caused profound (> 85%)
depletion of CD3+ (193050±62 vs. 2822639±18; p < 0.00002), CD4+
(147537±45 vs. 1850720±100; p < 0.00001) and CD8+ (53574±16 vs.
879043±58; p < 0.00002) cells in the lymph nodes compared to control
immunoglobulin (Ig) treated mice. Similar changes were seen in the spleen
(data not shown). Interestingly, there was no decrease in the number of
CD19+ cells with mATG (4167366±35 vs. 3434978±77; p = ns). Next, we
examined the kinetics of depletion and recovery of lymphocyte populations
following mATG in the full MHC-mismatched skin transplant recipients
7treated with or without mATG induction therapy. We noted profound (>
80%) and persistent depletion of CD3+, CD4+ and CD8+ T cells in the graft
draining lymph nodes particularly at day 7, but also 14 and 28 days after
transplantation compared to control Ig treated allograft recipients (Figure
1A). Similar changes were seen in spleen (data not shown). Again, there
was no decrease in the number of CD19+ cells in allograft recipients
treated with mATG induction therapy compared to control Ig at each of
these time-points (Figure 1A). Despite the profound depletion of T cells, we
noted significant preservation of number of Foxp3+ natural Tregs in naïve
mice at day 7 post-mATG induction therapy (166500±35770 vs
136900±15960, p=ns) and throughout the time-course in mATG treated
skin allograft recipients compared to control Ig treated recipients, resulting
in significantly higher percentage of Tregs at day 7 and 14 post-
transplantation; and in due course declining to levels seen in control
recipients by day 28 post-transplantation (Figure 1B). Similar changes
were seen in spleen (data not shown). This preservation of Tregs with
mATG however, led to only modest prolongation of the stringent full MHC-
mismatched skin allograft survival in recipients treated with mATG
induction therapy compared to control Ig treated recipients [median survival
time (MST) = 15.5 days vs. MST = 9 days respectively; p < 00004] (Figure
1C).
mATG synergizes with CTLA4Ig and SRL to prolong allograft survival
In an attempt to overcome the rejection of skin allograft despite profound T
cell depletion with mATG induction therapy, we initially combined CTLA4Ig
8with mATG and noted significant prolongation of stringent full MHC-
mismatched skin allograft survival in recipients treated with mATG
induction therapy and short course CTLA4Ig compared to recipients
treated with mATG induction therapy alone (MST = 36 days vs. MST =
15.5 days respectively; p < 0.003) (Figure 2A). Next, we examined the
effect of adding short-course sirolimus (SRL) to this regimen. Interestingly,
there was significant prolongation of graft survival in recipients treated with
combined mATG induction, short-course CTLA4Ig and SRL therapy
compared to mATG induction and short-course CTLA4Ig (MST = 58 days
vs. MST = 36 days respectively; p < 0.001) (Figure 2A). We then examined
the allospecific cytokine production, by splenocytes from full MHC-
mismatched skin allograft recipients, 7 days after transplantation. The
inhibition of graft rejection was associated with almost complete inhibition
of IFN-? and low but detectable production of IL-4 by splenocytes from
recipients treated with mATG induction therapy alone or in combination
with short-course CTLA4Ig+SRL (Figure 2B). Histological examination
showed well-preserved grafts with no evidence of rejection in grafts
harvested from recipients treated with combination therapy compared to
control Ig or mATG induction therapy alone (Figure 2C).
Beneficial effect of mATG alone or in combination with CTLA4Ig
and/or SRL on allograft survival is dependent on CD25+ T cells
To determine if prolonged allograft survival with mATG alone or in
combination with CTLA4Ig and/or SRL is dependent on Tregs, we
administered anti-CD25 mAb to the recipients prior to full MHC-
9mismatched skin transplantation. CD25+ T cell depletion prior to
transplantation led to abrogation of the beneficial effect of mATG induction
therapy alone or in combination with CTLA4Ig and/or SRL on allograft
survival (Figure 3A), indicating that Tregs are required for the graft
prolonging effect of mATG. Next, to investigate whether Treg generation by
the thymus or peripheral conversion of naïve T cells to Tregs and/or
expansion of preexisting Tregs in the periphery is responsible for the
beneficial effects of mATG, we performed thymectomy in the recipients 3
weeks prior to transplantation. Interestingly, thymectomy prior to
transplantation did not affect the graft prolonging effect of mATG induction
therapy whilst CD25+ T cell depletion in thymectomized recipients did
abrogate the graft prolonging effect of mATG (Figure 3B), indicating that
expansion of preexisting Tregs and/or peripheral conversion of naïve T cells
to Tregs is required for the beneficial effect of mATG on allograft survival.
CTLA4Ig and Sirolimus inhibit effector-memory differentiation and
promote regulation when combined with mATG
To further understand the mechanisms of graft prolongation with mATG-
based combination therapy, we utilized a novel TCR-transgenic-reporter
mouse model termed ABM-Foxp3GFPrep [with a TCR that utilizes the
V?2.1 and V?8.1 chains and specifically recognizes the MHC class II
molecule I-Abm12 – anti-bm12 (ABM) and expresses Foxp3-green
fluorescence protein (GFP)]. Utilizing microbeads system, we first isolated
CD4+ cells from Thy1.2+ABM-Fox3GFPrep mice and sorted for GFP+ and
GFP- populations by flow cytometry with > 98% purity. Then, 0.3x106
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CD4+Thy1.2+ABMFoxp3GFP+ or CD4+Thy1.2+ABMFoxp3GFP- cells were
injected in Thy1.1+C57BL/6 mice with or without bm12 skin transplantation.
In these mice we first studied the effect of mATG induction therapy on
antigen specific Treg (Thy1.2
+Foxp3GFP+) population by analyzing the
adoptively transferred CD4+Thy1.2+ABMFoxp3GFP+ cells. In keeping with
our previous in vitro observations (19), in the case of
CD4+Thy1.2+ABMFoxp3GFP+ cell-adoptive transfer, we found mATG
induction therapy preserved Thy1.2+Foxp3GFP+ cells and promoted their
expansion in vivo compared to control Ig treatment (391178±92 vs.
42911±19 respectively; p < 0.03) (Figure 4A). Further, in the case of
CD4+Thy1.2+ABMFoxp3GFP- cell-adoptive transfer, mATG significantly
promoted conversion of Thy1.2+Foxp3GFP- cells to Thy1.2+Foxp3GFP+
cells compared to control Ig treatment (529341±97 vs. 262120±96
respectively; p < 0.04) (Figure 4B). Despite the preferential preservation of
Thy1.2+Foxp3GFP+ cells and conversion of Thy1.2+Foxp3GFP- cells to
Thy1.2+Foxp3GFP+ cells with mATG, the effect of mATG induction therapy
on skin allograft survival was modest. We reasoned that rejection might be
occurring due to an increase in the Tem (Thy1.2
+Foxp3GFP-
CD44hiCD62Llo) populations in response to the alloantigen and/or
homeostatic proliferation in the aftermath of T cell depletion with mATG
induction therapy. Interestingly, combining mATG induction therapy with
short-course CTLA4Ig and SRL either individually or together affords
significant synergy in promoting allograft survival (Figure 2A). To
understand the mechanisms of this synergy, we next studied the effect of
mATG induction therapy in combination with CTLA4Ig and SRL individually
or together on antigen specific Treg (Thy1.2
+Foxp3GFP+) and Tem
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(Thy1.2+Foxp3GFP-CD44hiCD62Llo) populations and evaluated the Treg/Tem
ratio in various treatment groups 7 days after bm12 skin transplantation
utilizing the ABM-Foxp3GFPrep model. Interestingly we found that
combining CTLA4Ig or SRL with mATG induction therapy lead to not only
an increase in Thy1.2+Foxp3GFP+ cells by preservation and conversion but
also a significant inhibition of generation of Thy1.2+Foxp3GFP- cells with
the Tem phenotype (Thy1.2
+Foxp3GFP-CD44hiCD62Llo) resulting in a
favorable Treg/Tem ratio (Figure 4C).
mATG preserves Tregs which limit homeostatic proliferation of
memory cells following T cell depletion and the prolonged allograft
survival is dependent on favorable Treg/Tem balance
We investigated whether the Tregs spared by mATG limit homeostatic
proliferation of Tem cells and affect graft survival, by pre-depleting CD25
+
cells and then transplanting with full MHC-mismatched skin grafts or not
and treated with mATG induction therapy alone or in combination with
CTLA4Ig+SRL. We found that T cells that emerge in the aftermath of
depletion with mATG are more skewed towards a Tem (CD44
hiCD62Llo)
phenotype in both naïve and transplanted mice treated with mATG or
mATG+CTLA4Ig+SRL when CD25+ cells are pre-depleted compared to
controls (with no CD25+ cell depletion) (Table 1). Consequently, Treg/Tem
balance in naïve and transplanted mice is switched in favor of Tem cells
with CD25 pre-depletion and results in accelerated allograft rejection, most
dramatically in the mATG+CTLA4Ig+SRL group (Table 1).
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DISCUSSION
mATG, like the other preparations of anti-thymocyte globulins, depletes T
cells effectively both in naïve and transplanted animals (Figure 1A). In
keeping with our previous studies (19), Tregs were preferential spared from
depletion with mATG (Figure 1B). Naïve CD25+ T cells are resistant to
depletion by ALS and this is thought to be due to their higher expression of
anti-apoptotic gene Bcl-XL. Interestingly, on further analysis, Bcl-XL
expression appeared to be highest in Foxp3+ cells regardless of IL-2R ?-
chain (CD25) expression (22), explaining the relative sparing of Foxp3+
cells from the depletion effect of mATG in our studies (Figure 1B).
The fate of the alloimmune response is dependent on the balance between
alloreactive Tem and Tregs in vivo. mATG prolonged allograft survival by
profound T cell depletion and preferential sparing of Tregs (Figure 1B and
1C) and this effect was independent of recent thymic immigrants but
dependent on expansion of preexisting Tregs and/or peripheral conversion
of naïve T cells to Tregs (Figure 3B). Of note, the prolongation of graft
survival with mATG treatment was modest. This is particular clinical
relevance since homeostatic proliferation is thought to be barrier to
transplantation tolerance induction in both reconstituted scid mice and WT
mice treated with T cell-depleting antibodies (36). However, our data
suggests that mATG, unlike other T cell depleting therapies (26), preserves
Tregs (Figure 1B and 4). Further, these preserved Tregs themselves
undergo homoestatic proliferation as suggested by an elegant study which
showed CD4+CD25+ Treg cells are also capable
 of undergoing homeostatic
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proliferation in a lymphopenic environment and acquire memory-like
phenotype (CD44highCD45RBlow expression) with loss of CD25 and CD62L
expression but exhibit substantially augmented suppressive function (12).
Furthermore, Tregs are thought to play a major role in regulating
lymphopenia-induced T cell proliferation and acquisition of Tem phenotype
(10). Moreover, ex-vivo expanded antigen-specific natural Tregs synergize
with host T cell depletion and promote long-term allograft acceptance (37).
In keeping with these, our data suggests that mATG preserves CD25+
natural Tregs which limit skewing of T cell repertoire toward Tem phenotype
among the recovering T cells by inhibiting both lymphopenia-induced and
alloantigen-induced proliferation of T cells (Table 1).
B7/CD28 blockade with CTLA4Ig, on the other hand, has also been
demonstrated to be effective in controlling the homeostasis of Tem cells by
reducing expansion of central memory cells and migration of activated
memory CD4 cells to the periphery (25). Further, costimulation requirement
of alloreactive T cells is critically dependent on their precursor frequency,
where recipients with low CD4+ and CD8+ donor-reactive T cell frequencies
exhibited long-term skin graft survival upon CD28/CD154 blockade,
whereas simultaneously raising the frequency of CD4+ T cells to 0.5% and
CD8+ T cells to 5% precipitated graft rejection despite CD28/CD154
blockade (11). These taken together with our data (Figure 2A and 4),
indicate that T cell depletion with mATG may limit the precursor frequency
of alloreactive T cells and render them more susceptible to costimulation
blockade. Further, adding SRL to costimulation (B7-CD28 and CD40-
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CD40L pathways) blockade prolonged skin and heart graft survival in
murine models by two main mechanisms: inhibition of proliferation of
alloreactive T cells and induction of apoptosis of dividing alloreactive T
cells (18). A more recent study in human renal transplant recipients
demonstrated that combined treatment with ATG, SRL and mycophenolate
mofetil was associated with a progressive increase in Treg population both
in the periphery and in the graft infiltrating cells with concomitant decrease
of donor responsiveness in vitro (3). Moreover, both CTLAIg and SRL also
inhibit lymphopenia-induced and alloantigen-induced proliferation of T cells
(14, 23). Consistent with these data, we observed significant synergy on
combining mATG with CTLA4Ig and SRL individually or together (Figure
2A and 4). The beneficial effects of this combination therapy were
dependent on CD25+ Tregs indicating that Tregs are required for the graft
prolonging effect of combination therapy involving mATG (Figure 3A).
These data emphasize the advantage of this novel strategy of combining
mATG with T cell costimulatory blockade and SRL to preserve Tregs and
limit homeostatic proliferation of effector and memory T cells to promote
tolerance in human organ transplantation.
In summary, our data demonstrate that the combination of mATG with
costimulation blockade and sirolimus represents an effective strategy in
preventing allograft rejection and promoting graft acceptance in a full MHC-
mismatched stringent skin transplant model. The effectiveness of this
combination strategy depends not only on the depletion effects of mATG
but also on generating a favourable Treg/Tem balance. These data will serve
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as the basis of further studies in non-human primates to develop a clinically
applicable protocol to promote tolerance in transplantation.
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METHODS
Mice
C57BL/6 (B6, H-2b), BALB/c (H-2d), B6.PL-Thy1a/CyJ (Thy1.1 B6) and
B6.C.H-2 bm12 (bm12) mice were purchased from The Jackson
Laboratory. Foxp3GFP-ABM TCR-tg mice were generated by breeding
Foxp3GFP reporter mice, that expresses Foxp3-green fluorescence protein
(GFP), and ABM (anti-bm12) TCR-tg mice, a TCR-transgenic mouse
reactive to I-Abm12 (with a TCR that utilizes the V?2.1 and V?8.1 chains and
specifically recognizes the MHC class II molecule I-Abm12), both on the
C57BL/6 background and bearing the Thy 1.2 allele. Foxp3GFP-ABM mice
were maintained as a breeding colony in our animal facility. All mice were
used at 6–12 weeks of age and were housed in accordance with
institutional and National Institutes of Health guidelines.
Treatment Protocols
Murine Anti-Thymocyte globulin (mATG) is a purified, pasteurized, gamma
immune globulin, obtained by immunization of rabbits with mouse
thymocytes. It contains cytotoxic antibodies directed against antigens
expressed on murine T and non-T lymphocytes as well as a wide variety of
antigens as described previously (21, 5, 6, 27). mATG was administered at
a dose of 0.5 mg on day 0 and day 4 after transplantation as induction
therapy; CTLA4Ig (Abatacept) is a human IgG1 fusion protein obtained
from Bristol-Myers Squibb and was administered at a dose of 0.5 mg on
day 0 and 0.25 mg on days 2, 4, 6, 8 and 10. Sirolimus was a generous gift
of Wyeth Pharmaceuticals and administered at a dose of 0.3 mg/kg/day on
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days 0, 2, 4, 6, 8, and 10. CD25+ T cell depletion was achieved by treating
mice pre-operatively with 0.5 mg of anti-CD25 mAb (PC61) on days 6 and
1 before transplantation. All treatments were administered by
intraperitoneal injection.
Skin Transplantation
Full-thickness trunk skin grafts (1 cm2) harvested from BALB/c donors were
transplanted onto the flank of B6 recipient mice, sutured with 6.0 silk, and
secured with dry gauze and a bandage for 7 days. Skin graft survival was
monitored daily thereafter, and rejection was defined as complete graft
necrosis. For mechanistic studies bm12 skin was harvested and
transplanted onto the flank of Thy 1.1 B6 recipients mice with the same
technique.
Flow Cytometry Analysis
Recipient lymphocytes were isolated from the spleens and draining lymph
nodes (DLN) 7 days after transplantation, and red cells were lysed with
ACKLysis buffer (BioWhittaker). Cells were stained with anti-CD3-
fluorescein isothiocyanate (FITC), anti-CD19-phycoerytrin (PE), anti-CD8
allophycocyanin (APC) and anti-CD4-Peridinin Chlorophyl Protein (PerCP)
to assess the depletion effect of mATG; T effector-memory cells were
determined by staining with anti-CD4 PerCP, anti-CD8 FITC, anti-CD62
ligand (CD62L) APC, and anti-CD44 PE (all from BD Pharmingen) and
analyzed for cell bearing the CD44hiCD62Llow phenotype. Cells were also
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stained with NK1.1 PE, anti-CD11c APC and anti-CD80 PE, anti-CD11b
FITC and anti-F4/80 PE to identify NK cells, dendritic cell and
macrophages respectively. Regulatory T cells (Tregs) were detected by
staining with anti-CD4 FITC, anti-CD25 PE and intracellular staining with
Foxp3 APC (eBioscience) as per manufacturers instructions. Flow
cytometry was performed using a FACSCaliber flow cytometry system (BD
Biosciences) and analyzed using CellQuest software (BD Biosciences).
Results are representative of three experiments.
Adoptive transfer of Thy1.2+Foxp3GFPrep TCR-tg T cells
Adoptive transfer of Thy1.2+Foxp3GFPrep TCR-tg T cells was performed as
previously described in the ABM TCR-tg system (31). Briefly, spleens and
lymph nodes were harvested from Foxp3GFP-ABM mice and pooled
single-cell leukocyte suspensions were prepared. CD4+ T cells were
purified by magnetic bead positive selection (Miltenyi Biotec, Auburn, CA).
Typically, CD4+ T cells were isolated to > 90 % purity. An aliquot of cells
was stained with anti-CD4, anti-TCR V?2.1, and anti-TCR V?8.1, 8.2 and
analyzed by flow cytometry to determine the percentage of ABM TCR-tg
CD4+ T cells. ABM TCR-tg CD4+ T cells express CD90.2 (Thy 1.2+) on
their surface. Typically, > 90% of CD4+ T cells expressed the tg TCR, and
2% of CD4+ T cells was determined as GFP+. CD4+ isolated cells were
then flow sorted for GFP+/- cells with a 97% of purity. 0.3 x 106
Thy1.2+Foxp3GFP positive or negative cells were then injected
intraperitoneally into Thy 1.1 B6 mice one day before skin transplantation
(day –1). On day 7 following transplantation draining (axillary, lateral
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axillary) lymph nodes and spleens were subsequently collected, single-cell
leukocyte suspensions were prepared and Thy1.2+Foxp3GFP+/- TCR-tg T
cells were identified by flow cytometry.
ELISPOT assay
The technique for enzyme linked immunospot (ELISPOT) analysis was
adapted to measure IFN-? and IL-4 secreting cells. Immunospot plates
(Cellular Technology) were coated with capture antibodies against IFN-?
(R4-6A2) or IL-4 (11B11) in sterile PBS overnight. The plates were then
blocked for 1 h with sterile PBS containing 1% BSA-fraction V and washed
three times with sterile PBS. Splenocytes (0.5 x 106 in 200 ?l of HL-1
medium containing 1% L-glutamine) were then placed in each well in the
presence of 0.5 x 106 irradiated (30 Gy) syngeneic or allogeneic
splenocytes and cultured for 24 h (for IFN-?), or 48 h (IL-4) at 37°C in 5%
CO2. After washing with PBS followed by washing with PBS containing
0.05% Tween (PBST), biotinylated rat anti-mouse IFN-? (XMG1.2) and IL-4
(BVD6-24G2) detection mAb was added overnight. All Abs were purchased
from BD Pharmingen. The plates were then washed four times in PBST,
followed by 2 h of incubation with HRP-conjugated streptavidin (DAKO)
diluted at 1/2000 in PBS/1% BSA. After washing three times with PBST
followed by PBS, the plates were developed using 3-amino-9-ethyl-
carbazole (Sigma-Aldrich). The resulting spots were counted on a
computer-assisted ELISPOT image analyzer (Cellular Technology), and
frequencies were expressed as the number of cytokine-producing spots
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per 0.5 x 106 splenocytes (mean ± SD). Results are representative of three
separate experiments.
Immunohistochemistry staining
Skin graft samples were obtained at each time point in each group of
treatment; part of the skin graft was fixed in OCT and part in formalyn 10%,
they were sectioned and stained with H&E for evaluation of cellular
infiltration. The infiltrating cells were stained for CD4, CD8, macrophages
(Mac1) and Foxp3 following the standard protocol.
Statistics
Kaplan-Meier survival graphs were constructed and a log rank comparison
of the groups was used to calculate p values. Student’s t test was used for
comparison of means between experimental groups examined by FACS
analysis or ELISPOT assay. Differences were considered to be significant
at p values < 0.05.
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FIGURES AND TABLES
FIGURES 
Figure 1: mATG depletes naïve T cells, preserves natural Tregs and 
prolongs allograft survival 
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Fig.1A. Line graphs depicting absolute numbers of CD3+ (upper left panel), 
CD4+ (upper right panel), CD8+  (lower left panel) and CD19+  (lower right 
panel) cells 7, 14 and 28 days after transplantation with mATG induction or 
control Ig treatment. 
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Figure 1B. Line graphs depicting absolute numbers (left panel) and 
percentage (right panel) of Tregs 7, 14 and 28 days after transplantation 
with mATG induction or control Ig treatment. C. Kaplan-Meier graphs 
depicting full MHC-mismatched skin allograft survival with mATG induction 
or control Ig treatment. 
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Figure 1C. Kaplan-Meier graphs depicting full MHC-mismatched skin 
allograft survival with mATG induction or control Ig treatment. 
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Figure 2: Combination therapy synergizes to prolong graft survival, 
inhibit allospecific cytokine production and preserves graft histology  
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Figure 2A. Kaplan-Meier graphs depicting full MHC-mismatched skin 
allograft survival with mATG in combination with CTLA4Ig and/or SRL or 
mATG induction alone. 
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Figure 2B. Bar graphs depicting production of allospecific cytokine IFN- 
(left panel) and IL-4 (right panel), by ELISPOT assay with splenocytes from 
full MHC-mismatched skin allograft recipients, 7 days after transplantation 
with various treatments. 
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Figure 2C. H and E stained light micrographs depicting features of acute 
rejection in grafts harvested 7 days after transplantation from recipients 
treated with control Ig (left upper panel); minimal infiltration of grafts 
harvested 7 days after transplantation (right upper panel) compared to 
features of acute rejection in grafts harvested 14 days after 
transplantation from recipients treated with mATG induction therapy 
alone; well-preserved graft with no evidence of rejection in grafts 
harvested from recipients treated with combination therapy (lower right 
panel). 
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Figure 3: Prolonged allograft survival with mATG alone or in 
combination with CTLA4Ig and/or SRL is dependent on CD25
+
 T cells 
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Figure 3A. Kaplan-Meier graphs depicting full MHC-mismatched skin 
allograft survival with CD25 pre-depletion and mATG in combination with 
CTLA4Ig and/or SRL or mATG induction alone. 
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Figure 3B. Kaplan-Meier graphs depicting full MHC-mismatched skin 
allograft survival in thymectomized or non-thymectomized recipients with or 
without CD25 pre-depletion and mATG induction therapy. 
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 Figure 4: CTLA4Ig and Sirolimus inhibit effector-memory 
differentiation and promote favourable Treg/Teff-mem balance when 
combined with mATG 
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Figure 4A. Bar graphs depicting absolute numbers of Thy1.2+FoxpGFP+ or 
Thy1.2+Foxp3GFP- populations 7 days after transplantation, in both lymph 
nodes and spleen from recipients adoptively transferred with 
Thy1.2+Foxp3GFP+ cells and treated with mATG induction therapy alone, 
in combination with CTLA4Ig and/or SRL or control Ig. Representative 
histograms of Thy1.2+FoxpGFP+ cells from recipients in each treatment 
group are shown below respective bar graphs. 
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Figure 4B. Bar graphs depicting absolute numbers of Thy1.2+FoxpGFP+ or 
Thy1.2+Foxp3GFP- populations 7 days after transplantation, in both lymph 
nodes and spleen from recipients adoptively transferred with 
Thy1.2+Foxp3GFP- cells and treated with mATG induction therapy alone, in 
combination with CTLA4Ig and/or SRL or control Ig. Representative 
histograms of Thy1.2+FoxpGFP+ cells from recipients in each treatment 
group are shown below respective bar graphs. 
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Figure 4C. Scatter plots depicting Treg/Teff-mem ratios 7 days after 
transplantation, in both lymph nodes and spleen from recipients adoptively 
transferred with Thy1.2+Foxp3GFP+ (left panel) or Thy1.2+Foxp3GFP- (right 
panel) cells and treated with mATG induction therapy alone, in combination 
with CTLA4Ig and/or SRL or control Ig. 
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TABLES 
Table 1: mATG preserves Tregs which limit homeostatic proliferation of 
memory cells following T cell depletion 
Therapy Tx CD25  
pre-
depletion 
Treg 
(%) 
Teff (%) Treg/Teff 
Ratio 
MST 
(days) 
mATG No No 411 41.43 1 NA 
mATG No Yes 18.33; 
p<0.001 
55.42; 
p<0.007 
0.3; 
p<0.001 
NA 
mATG Yes No 445 31.42 1.5 15.5 
mATG Yes Yes 390.5; 
p=ns 
605; 
p<0.02 
0.7; 
p<0.04 
12.5; 
p<0.003 
mATG 
+CTLA4Ig
+SRL 
Yes No 339 4010 0.8 58 
mATG 
+CTLA4Ig
+SRL 
Yes Yes 51; 
p<0.002 
761; 
p<0.001 
0.05; 
p<0.0006 
25; 
p<0.001 
 
All p values are in comparison with no CD25 depletion in the respective 
group 
  
